Published in Women's Health Weekly, October 26th, 2000
In accordance with an agreement reached with the FDA, Genelabs used the rolling NDA process for submitting the NDA, a benefit of Fast Track designation, which was previously granted to GL701 for SLE. The company began the filing process in May 2000 with submission of the complete clinical efficacy and safety data.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.